Daiichi, AZ TROP2 ADC shows numerical advantages over Trodelvy

Initial data from Daiichi and AstraZeneca’s TROP2-targeted ADC shows some numerical advantages over Phase III data from Gilead’s Trodelvy in hormone receptor-positive, HER2-low or -negative metastatic breast cancer. But the two show little difference so far in triple-negative breast cancer.

In the HR-positive, HER2-low or -negative setting in the Phase I TROPION-PanTumor01 study, datopotamab deruxtecan from Daiichi Sankyo Co. Ltd. (Tokyo:4568) and AstraZeneca plc (LSE:AZN; NASDAQ:AZN) showed a numerically superior objective response rate (ORR) and median progression-free survival (PFS) vs. data reported by Gilead Sciences Inc. (NASDAQ:GILD) in the Phase III TROPiCS-02 study of Trodelvy sacituzumab govitecan. ...